Astria Therapeutics Soars 2.82%: Nasdaq Listing Boosts Shares!

miércoles, 4 de junio de 2025, 9:48 am ET1 min de lectura
ATXS--
Astria Therapeutics, Inc. rose 2.82% intraday, with the company announcing inducement grants under Nasdaq listing rules. The company is focused on developing therapies for allergic and immunological diseases, with its lead program, STAR-0215, in clinical development for hereditary angioedema (HAE). Additionally, the company's second program, STAR-0310, is in preclinical development for atopic dermatitis (AD).

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios